

AngioJet Rheolytic Thrombectomy In Patients With Thrombolysis In Myocardial Infarction Thrombus Grade 5: An Observational Study

Yi-xiong Huang

Medical School of Chinese People's Liberation Army General Hospital

Yi Cao

Sixth Medical Center of Chinese People's Liberation Army General Hospital

Yu Chen

Sixth Medical Center of Chinese People's Liberation Army General Hospital

Yi-gang Qiu

Sixth Medical Center of Chinese People's Liberation Army General Hospital

Jian-yong Zheng

Sixth Medical Center of Chinese People's Liberation Army General Hospital

Ying-ming Liu

Sixth Medical Center of Chinese People's Liberation Army General Hospital

Jiang-chun He

Sixth Medical Center of Chinese People's Liberation Army General Hospital

Tian-chang Li (✉ ltc909@163.com)

Sixth Medical Center of Chinese People's Liberation Army General Hospital

Research Article

Keywords: Thrombectomy, STEMI, Propensity-score matching, Percutaneous Coronary Intervention

Posted Date: September 9th, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-871860/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Abstract

OBJECTIVES The aim of this study was to evaluate the effectiveness and safety of AngioJet rheolytic thrombectomy among patients with high thrombus burden.

BACKGROUND Routine manual thrombus aspiration in patients with ST-segment elevation myocardial infarction (STEMI) does not improve clinical outcomes and was associated with an increased rate of stroke. However, the safety of mechanical thrombus aspiration is still unknown.

METHODS This was a single-center study involving 621 patients with Thrombolysis In Myocardial Infarction thrombus grade 5. The primary outcome was the composite of major adverse cardiovascular events (MACE) within 12 months. The safety outcome was stroke within 1-year.

RESULTS AngioJet rheolytic thrombectomy was performed in 117 patients. After propensity-score matching, there was no significant difference both in the incidence of MACE (11.1% vs 17.9%, hazard ratio, 1.641; 95% confidence interval [CI], 0.822 to 3.277, $p=.161$) and the incidences of stroke (1.7% vs 2.6%, hazard ratio, 1.522; 95% confidence interval [CI], 0.254 to 9.107, $p=.646$) between two groups at 1-year follow-up.

CONCLUSIONS In patients with Thrombolysis In Myocardial Infarction thrombus grade 5, AngioJet rheolytic thrombectomy did not improve clinical outcomes at 1 year. However, AngioJet rheolytic thrombectomy did not increase the risk of stroke in patients with high thrombus burden.

Introduction

High thrombus burden is a predicting factor of poor prognosis in patients with ST-Segment elevation myocardial infarction (STEMI) ^{1,2}. Previous studies failed to show the benefit of routine thrombus aspiration in patients with STEMI by using manual aspiration catheter ³⁻⁵. Similar result was observed in the subgroup of high thrombus burden, which was also showed an increased rate of stroke at 1 year in routine thrombus aspiration group ⁶. Accordingly, routine use of thrombus aspiration is not recommended in the guidelines for the management of acute myocardial infarction base on the evidence of TALOR study ⁷. However, the effectiveness of manual thrombus aspiration is susceptible to operating techniques. The increased risk of stroke in the manual thrombus aspiration group might be pertinent to the detachment of thrombus from aspiration catheter ⁸. Mechanical thrombus aspiration is accomplished with high velocity saline jets leading to a low-pressure zone (Bernoulli effect), which is more effective in thrombus removal than manual aspiration. Thus, mechanical removal of thrombus among patients with STEMI may be associated with improved outcomes and avoiding migrant thrombus. Moreover, the selection of suitable candidates and the best time for applying thrombus aspiration are still controversial. Base on previous evidences, we only performed thrombus aspiration in patients with Myocardial Infarction Thrombus Grade 5 (total occlusion caused by thrombus before wire crossing) ⁹. We analyzed the data of consecutive patients diagnosed with STEMI who received AngioJet rheolytic thrombectomy to

investigate the efficacy and safety of mechanical thrombus aspiration in patients with high thrombus burden.

Materials And Methods

Study design and population

This was a single-center study. Patients diagnosed with STEMI admitted to the Sixth Medical Center of Chinese People's Liberation Army General Hospital from October 2014 to April 2019 were enrolled consecutively. All participants met the diagnostic criteria of STEMI according to the universal definition of myocardial infarction¹⁰: detection of a rise of cardiac troponin with at least one value above the 99th percentile upper reference limit and with at least one of following: symptoms of ischemia; new or presumed new significant ST-segment-T wave changes or new left bundle branch block; development of pathological Q waves in the electrocardiogram; imaging evidence of new loss of viable myocardium or new regional wall motion abnormality. Exclusion criteria were an age younger than 18 years, a rejection of invasive surgery, a contraindication of PCI, severe tortuous and calcified lesion, vessel diameter of culprit lesion less than 2.5mm, the need for emergency coronary artery bypass.

Ethics Committee of the Sixth Medical Center of Chinese People's Liberation Army General Hospital specially approved that not informed consent was required because data were going to be analyzed anonymously.

Cardiac catheterisation and coronary intervention

All patients received dual antiplatelet therapy (aspirin 300mg loading dose and a P2Y₁₂ receptor inhibitor: clopidogrel 300/600mg loading dose or ticagrelor 180mg loading dose) before coronary angiography. The use of glycoprotein IIb/IIIa inhibitors or low molecular heparin was left to the discretion of the operator. An intra-aortic balloon pump (IABP) was used or not based on the patient's hemodynamic status.

AngioJet rheolytic thrombectomy were only performed in patients with high thrombus burden (Thrombolysis In Myocardial Infarction thrombus grade 5). The AngioJet Ultra thrombectomy system (Boston Scientific) consists of a 4-F aspiration catheter, a pump set, and a drive unit console. Prime the catheter by heparinized saline until the time display reaches zero seconds. Activating the device at least 1 cm proximal to the thrombus before advancing beyond the lesion, advancement speed of 2 mm per second, and keeping the device activated during multiple passages until all visible thrombus disappears. Single suction time should be less than 5 seconds to avoid transient bradycardia. Repeat suction should be deployed while TIMI flow did not restore or residual thrombus was detected by angiography.

Study end point

The primary outcome was the composite of major adverse cardiovascular events (MACE) including death, heart failure, rehospitalization for unstable angina, and target vessel revascularization within 12

months. The safety outcome was stroke within 1-year. Follow-up visits were required for all patients at the time of 1 month, 3 months, 6 months, and 12 months after angiography. Patients live in a remote area were followed by phone calls.

Statistical analysis

The data were analyzed by SPSS version 26.0 for window (SPSS Inc., Chicago, IL, USA). The normality of distribution of continuous variables was tested by one-sample Kolmogorov-Smirnov test. Continuous variables with normal distribution were presented as mean (standard deviation [SD]); non-normal variables were reported as median (interquartile range [IQR]). The frequencies of categorical variables were compared using Pearson χ^2 or Fisher's exact test.

Due to the significant baseline differences between two groups, the propensity-score matching method was used. Matching was performed with the use of a 1:1 matching protocol without replacement (greedy-matching algorithm), with a caliper width equal to 0.01 of the standard deviation of the logic of the propensity score.

The time to death within 1 year after angiography according to study group is presented in a Kaplan–Meier plot. Hazard ratios for the primary end point and for all end points assessed through 1 year were calculated with the use of a Cox proportional-hazards model with treatment as the only factor and are shown with the nominal 95% confidence interval from the Cox model and the nominal two-sided P value from a log-rank test. All tests were 2-sided and a $P < 0.05$ was considered significant.

The authors confirm that all methods were carried out in accordance with relevant guidelines and regulations. The authors confirm that all experimental protocols were approved by Ethics Committee of the Sixth Medical Center of Chinese People's Liberation Army General Hospital.

Results

Baseline characteristic

There were 877 consecutive patients diagnosed with STEMI from October 2014 to April 2019. Five hundred and fifty-six of these with TIMI thrombus grade 5 (total occlusion caused by thrombus before wire crossing) were enrolled. Fifteen patients who did not perform PCI were excluded. Three cases were lost to follow-up. Enrolled patients were divided into 2 groups: AngioJet rheolytic thrombectomy group (AT, $n = 117$), routine treatment group (RT, $n = 439$). After propensity-score matching, 117 patients in each group were included in the analysis (Fig. 1).

Baseline clinical characteristics of patients before and after propensity-score matching are listed in Table 1. The AT group was younger and had more men than the RT group. There were less delay PCI and IABP used in the AT group as compared with the RT group. Systolic blood pressure was lower in the AT group at admission. In-hospital data are shown in Table 2. The AT group had higher cardiac troponin I both at admission and peak value as compared with the RT group. Hemoglobin and estimated glomerular

filtration rate were significantly higher in the AT group, while brain natriuretic peptide was significantly higher in the RT group. P2Y₁₂ inhibitor, statin, β -blocker, and glycoprotein IIb/IIIa inhibitor were used more often in the AT group.

Table 1
Baseline Characteristics before and after Propensity-Score Matching.

Characteristic	Before Matching			After Matching		
	AT group (n = 117)	RT group (n = 421)	p value	AT group (n = 117)	RT group (n = 117)	p value
Age, yr	60.9 ± 13.9	64.2 ± 13.4	0.019	60.9 ± 13.9	61.1 ± 13.4	0.910
Male (%)	102 (87.2)	322 (76.5)	0.012	102 (87.2)	102 (87.2)	1.000
BMI (kg/m ²)	25.4 ± 3.52	25.3 ± 3.37	0.759	25.4 ± 3.52	25.9 ± 3.39	0.232
Diabetes mellitus (%)	28 (23.9)	127 (30.2)	0.188	28 (23.9)	29 (24.8)	0.879
Hypertension (%)	63 (53.8)	222 (52.7)	0.831	63 (53.8)	48 (41.0)	0.050
Dyslipidemia (%)	20 (17.1)	58 (13.8)	0.367	20 (17.1)	19 (16.2)	0.861
Current smoking (%)	66 (56.4)	200 (47.5)	0.088	66 (56.4)	64 (54.7)	0.792
Previous MI (%)	7 (6.0)	34 (8.1)	0.450	7 (6.0)	4 (3.4)	0.354
Previous PCI (%)	8 (6.8)	37 (8.8)	0.500	8 (6.8)	6 (5.1)	0.581
Previous stroke (%)	17 (14.5)	56 (13.3)	0.731	17 (14.5)	14 (12.0)	0.563
Killip class \geq II (%)	16 (13.7)	91 (21.6)	0.057	16 (13.7)	16 (13.7)	1.000
Delayed PCI (%)†	3 (2.6)	62 (14.7)	0.000	3 (2.6)	5 (4.3)	0.722
IABP (%)	4 (3.4)	52 (12.4)	0.005	4 (3.4)	5 (4.3)	1.000
Number of stents	1.27 ± 0.60	1.32 ± 0.75	0.550	1.27 ± 0.60	1.29 ± 0.78	0.850
SBP at admission (mmHg)	117.4 ± 19.5	122.4 ± 21.7	0.024	117.4 ± 19.5	122.8 ± 23.0	0.054
DBP at admission (mmHg)	71.5 ± 12.4	73.2 ± 13.6	0.204	71.5 ± 12.4	73.1 ± 14.5	0.354
BMI: body mass index, MI: myocardial infarction, PCI: percutaneous coronary intervention, IABP: Intra aortic balloon pump, SBP: systolic blood pressure, DBP: diastolic blood pressure.						
†Delayed PCI: the time of PCI from symptom onset \geq 12 h						

Table 2
In-hospital data before and after Propensity-Score Matching.

Characteristic	Before Matching			After Matching		
	AT group (n = 117)	RT group (n = 421)	p value	AT group (n = 117)	RT group (n = 117)	p value
cTnl at admission (ng/ml)	46.1 ± 38.8	36.5 ± 34.9	0.017	46.1 ± 38.8	51.3 ± 43.9	0.347
cTnl peak (ng/ml)	58.9 ± 34.5	44.1 ± 33.8	0.000	58.9 ± 34.5	61.4 ± 40.4	0.624
CK-MB at admission (ng/ml)	213.7 ± 179.0	188.6 ± 181.4	0.185	213.7 ± 179.0	165.2 ± 143.9	0.023
CK-MB peak (ng/ml)	238.6 ± 173.9	220.8 ± 187.8	0.357	238.6 ± 173.9	199.5 ± 168.3	0.082
Hemoglobin (g/L)	140.6 ± 14.5	135.4 ± 21.0	0.003	140.6 ± 14.5	139.5 ± 19.3	0.631
eGFR (ml/min/1.73 m ²)	81.6 ± 22.5	76.6 ± 22.6	0.036	81.6 ± 22.5	82.9 ± 20.3	0.629
TC (mmol/L)	4.77 ± 1.16	4.70 ± 1.21	0.577	4.77 ± 1.16	4.92 ± 1.34	0.345
TG (mmol/L)	1.38 ± 0.94	1.55 ± 1.36	0.123	1.38 ± 0.94	1.80 ± 1.86	0.029
HDL (mmol/L)	1.21 ± 0.33	1.20 ± 0.32	0.815	1.21 ± 0.33	1.23 ± 0.30	0.630
LDL (mmol/L)	2.59 ± 0.78	2.60 ± 0.87	0.933	2.59 ± 0.78	2.56 ± 0.82	0.718
INR	1.14 ± 0.38	1.18 ± 0.55	0.440	1.14 ± 0.38	1.12 ± 0.27	0.654
BNP (pg/ml)	212.7 ± 303.5	369.7 ± 523.9	0.000	212.7 ± 303.5	289.8 ± 363.2	0.091
Aspirin (%)	114 (97.4)	388 (92.2)	0.043	114 (97.4)	113 (96.6)	1.000
P2Y ₁₂ inhibitor (%)	114 (97.4)	386 (91.7)	0.032	114 (97.4)	111 (94.9)	0.499
PPI (%)	69 (59.0)	252 (60.0)	0.841	69 (59.0)	63 (53.8)	0.429
Statin (%)	114 (97.4)	387 (91.9)	0.037	114 (97.4)	111 (94.9)	0.499
ACEi or ARB (%)	81 (69.2)	272 (64.6)	0.352	81 (69.2)	78 (66.7)	0.674
β-blocker (%)	91 (77.8)	286 (67.9)	0.040	91 (77.8)	76 (65.0)	0.030

cTnl: cardiac troponin I, CK-MB: creatine kinase-MB, eGFR: estimated glomerular filtration rate, TC: total cholesterol, TG: triglyceride, HDL: high-density lipoprotein, LDL: low-density lipoprotein, INR: international normalized ratio, BNP: Brain natriuretic peptide, PPI: proton pump inhibitor, ACEi: angiotensin-converting enzyme inhibitor, ARB: angiotensin receptor, MRA: mineralocorticoid receptor antagonist, GP: glycoprotein, LVEF: left ventricular ejection fraction.

Characteristic	Before Matching			After Matching		
	AT group (n = 117)	RT group (n = 421)	p value	AT group (n = 117)	RT group (n = 117)	p value
MRA (%)	17 (14.5)	74 (17.6)	0.437	17 (14.5)	15 (12.8)	0.704
Low molecular heparin (%)	4 (3.4)	15 (3.6)	0.940	4 (3.4)	3 (2.6)	1.000
GP β / α inhibitor (%)	89 (76.1)	218 (51.8)	0.000	89 (76.1)	94 (80.3)	0.429
LVEF (%)	52.9 \pm 8.84	53.5 \pm 8.60	0.510	52.9 \pm 8.84	53.6 \pm 9.19	0.567
Length of stay (days)	10.6 \pm 4.01	11.7 \pm 6.39	0.020	10.6 \pm 4.01	10.9 \pm 5.95	0.616

cTnI: cardiac troponin I, CK-MB: creatine kinase-MB, eGFR: estimated glomerular filtration rate, TC: total cholesterol, TG: triglyceride, HDL: high-density lipoprotein, LDL: low-density lipoprotein, INR: international normalized ratio, BNP: Brain natriuretic peptide, PPI: proton pump inhibitor, ACEi: angiotensin-converting enzyme inhibitor, ARB: angiotensin receptor, MRA: mineralocorticoid receptor antagonist, GP: glycoprotein, LVEF: left ventricular ejection fraction.

After propensity-score matching, there were fewer differences in the baseline clinical and interventional features. Creatine kinase-MB at admission was higher in the AT group compared with the RT group. However, there was no significant difference in the peak value of creatine kinase-MB. The triglyceride level was significantly lower in the AT group. There was still more β -blocker used in the AT group after propensity-score matching.

Clinical outcomes

Clinical outcomes of the 1-year follow-up before and after propensity matching are shown in Table 3. By 1 year follow-up, the rate of MACE was significantly lower in the AT group as compared with the RT group (11.1% vs 21.6%, hazard ratio, 0.483; 95% confidence interval[CI], 0.270 to 0.863, $p = .014$). The difference was driven by all-cause mortality (4.3% vs 12.8%, hazard ratio, 3.127; 95% confidence interval[CI], 1.251 to 7.818, $p = .015$). There was no significant difference in the incidence of stroke between two groups at 1-year follow-up in all patients (1.7% vs 1.9%, hazard ratio, 1.201; 95% confidence interval[CI], 0.255 to 5.656, $p = .817$).

Table 3
Clinical outcomes at 1 year before and after Propensity-Score Matching.

	Before Matching			After Matching		
	AT group (n = 117)	RT group (n = 421)	p value	AT group (n = 117)	RT group (n = 117)	p value
MACE (%)	13 (11.1)	91 (21.6)	0.014	13 (11.1)	21 (17.9)	0.161
Death (%)	5 (4.3)	54 (12.8)	0.015	5 (4.3)	8 (6.8)	0.398
Heart failure (%)	5 (4.3)	21 (5.0)	0.621	5 (4.3)	6 (5.1)	0.741
Rehospitalization (%)	2 (1.7)	13 (3.1)	0.369	2 (1.7)	5 (4.3)	0.264
TVR (%)	2 (1.7)	8 (1.9)	0.811	2 (1.7)	3 (2.6)	0.643
Stroke (%)	2 (1.7)	8 (1.9)	0.817	2 (1.7)	3 (2.6)	0.646
TVR: Target vessel revascularization						

After propensity-score matching, there was no significant difference in the incidence of MACE between two groups (11.1% vs 17.9%, hazard ratio, 1.641; 95% confidence interval[CI], 0.822 to 3.277, $p = .161$). Although the death rate was lower in the AT group as compared with RT group, the difference was not significant (4.3% vs 6.8%, hazard ratio, 1.619; 95% confidence interval[CI], 0.530 to 4.948, $p = .398$). Kaplan–Meier Curves for Death from Any Cause are showed in the Fig. 2. The incidence of stroke was still not significant difference between two groups after propensity-score matching (1.7% vs 2.6%, hazard ratio, 1.522; 95% confidence interval[CI], 0.254 to 9.107, $p = .646$). Additionally, there was no significant effect of AngioJet Rheolytic thrombectomy on heart failure, rehospitalization, target vessel revascularization before and after propensity-score matching.

Discussion

The main finding of our study is that AngioJet rheolytic thrombectomy with PCI in patients with TIMI thrombus grade 5 did not reduce all-cause mortality, heart failure, rehospitalization, target vessel revascularization as compared with routine treatment at 1-year follow-up. However, unlike manual thrombus aspiration, AngioJet rheolytic thrombectomy did not increase the risk of stroke in patients with high thrombus burden.

High thrombus burden is associated with poor myocardial perfusion and adverse clinical outcomes^{6, 11}. An individual patient Meta-Analysis showed that manual thrombus aspiration was associated with fewer cardiovascular deaths (170 [2.5%] versus 205 [3.1%]; hazard ratio, 0.80; 95% confidence interval, 0.65–0.98; $P = .03$) and with more strokes or transient ischemic attacks (55 [0.9%] versus 34 [0.5%]; odds ratio, 1.56; 95% confidence interval, 1.02–2.42, $P = .04$)¹². In the Chinese population of TOTAL trial, manual thrombus aspiration was significantly associated with a nearly sevenfold increased risk of stroke at 5 years compared with PCI alone¹³. The risk of stroke might be correlated with embolization of thrombus

from the coronary artery to systemic circulation. AngioJet rheolytic thrombectomy is achieved by injecting pressurized saline through a hypotube by the distal tip of the coronary catheter, thereby leading to a low-pressure zone (Bernoulli effect). Thrombus is fragmented by the saline jets out of the catheter before being evacuated from the body through the catheter. A comparison of manual thrombus aspiration with rheolytic thrombectomy by optical coherence tomography showed that rheolytic thrombectomy group had a lower residual thrombotic burden as compared with manual aspiration¹⁴. Therefore, rheolytic thrombectomy is more effective in thrombus removal than manual aspiration, which might be the main reason why rheolytic thrombectomy did not increase the risk of stroke in our study.

So far, the results of randomized trials on rheolytic thrombectomy in patients with STEMI were controversial. The JETSTENT trial, which enrolled 501 patients with thrombus grade 3 to 5, showed a higher event-free survival rate as compared with direct stenting alone¹⁵. The MUSTELA trial revealed that thrombectomy had a better post-procedural ST-segment elevation resolution and reduced microvascular obstruction at 3 months in patients with high thrombus load by using Export catheter and AngioJet Ultra catheter in a sequential alternating fashion¹⁶. On the contrary, the AiMI trial showed increased 1-month mortality and major adverse cardiovascular event (MACE) rate in patients treated with rheolytic thrombectomy as compared with PCI alone¹⁷. The inconsistencies of these results may be associated with study design, limited sample size, technique, and selection bias of the patients.

Our study showed that AngioJet rheolytic thrombectomy had a significantly lower mortality than the routine treatment group in all patients with TIMI thrombus grade 5. The death rate was still lower in the AT group after propensity-score matching (4.3% vs 6.8%), but the difference was not statistically significant. As it was a non-randomized retrospect study, there may exist selection bias. The patients underwent AngioJet rheolytic thrombectomy had a higher thrombus burden in real-world experiences since operators won't take into account thrombus aspiration in patients with mild thrombus burden. The creatine kinase-MB at admission was significantly higher in the AT group, which indicated that the patients of the AT group might have a larger infarct size. Hence, the patients of the AT group might have a more serious clinical condition than the RT group. Patients who are at high risk of adverse outcomes tend to have the maximum benefit from a given treatment, which is called as "quantitative interaction"¹⁸. A real-world study enrolled 9100 patients diagnosed with STEMI showed that selective aspiration thrombectomy at the operation's discretion had a comparable mortality rate compared with PCI alone and did not increase the risk of stroke¹⁹.

Previous studies revealed that patients with high risk might benefit from thrombus aspiration^{20, 21}. Ruben et al have reported that rheolytic thrombectomy was associated with a lower target vessel revascularization in patients with acute myocardial infarction complicated by cardiogenic shock²². Ahmed et al found that thrombus aspiration might be associated with improved reperfusion and myocardial salvage especially in STEMI patients presenting after 12 h from symptom onset²³. Accordingly, further investigations on AngioJet rheolytic thrombectomy among patients with high risk is warranted.

Our study has several limitations. First, this is a non-randomized retrospective study. Although propensity-score matching was used, the baseline characteristics can not be matched utterly. There might be selection bias which might influence the findings. Second, our study lack of surrogate markers of myocardial reperfusion, such as myocardial blush grade, ST-segment resolution, or infarct size. Finally, our research was a single-center study with a small sample size. A large multicenter trial is warranted to shed light on the benefit and safety of AngioJet rheolytic thrombectomy in patients with high thrombus burden.

Conclusion

In patients with Thrombolysis In Myocardial Infarction thrombus grade 5, AngioJet rheolytic thrombectomy did not improve clinical outcomes at 1 year. Meanwhile, AngioJet rheolytic thrombectomy did not increase the risk of stroke in patients with high thrombus burden.

Declarations

FUNDING

None.

Acknowledgements

We gratefully acknowledge the assistance of proof-readers and editors.

Author contributions

Each author have contributed significantly to the submitted work. Yi-xiong Huang, Yu Chen, and Tian-chang Li designed the study. Yi-xiong Huang drafted the manuscript. Yi Cao, Yi-gang Qiu, and Ying-ming Liu revising it critically for important intellectual content. Jiang-chun He, Li Zhao and Jian-yong Zheng have contributed to the analysis and interpretation of data. Tian-chang Li, the corresponding author of this manuscript, final approved the manuscript submitted.

Conflict of interest: The authors confirm that this article content has no conflicts of interest.

Disclosure statement: The authors report no financial relationships or conflicts of interest regarding the content herein.

References

1. Sianos G, Papafaklis MI, Daemen J, et al. Angiographic stent thrombosis after routine use of drug-eluting stents in ST-segment elevation myocardial infarction: the importance of thrombus burden. *J Am Coll Cardiol*. Aug 14 2007;50(7):573-83. doi:10.1016/j.jacc.2007.04.059

2. Napodano M, Dariol G, Al Mamary AH, et al. Thrombus burden and myocardial damage during primary percutaneous coronary intervention. *Am J Cardiol.* May 1 2014;113(9):1449-56. doi:10.1016/j.amjcard.2014.01.423
3. Lagerqvist B, Frobert O, Olivecrona GK, et al. Outcomes 1 year after thrombus aspiration for myocardial infarction. *N Engl J Med.* Sep 18 2014;371(12):1111-20. doi:10.1056/NEJMoa1405707
4. Jolly SS, Cairns JA, Yusuf S, et al. Outcomes after thrombus aspiration for ST elevation myocardial infarction: 1-year follow-up of the prospective randomised TOTAL trial. *Lancet.* Jan 9 2016;387(10014):127-35. doi:10.1016/S0140-6736(15)00448-1
5. Frobert O, Lagerqvist B, Olivecrona GK, et al. Thrombus aspiration during ST-segment elevation myocardial infarction. *N Engl J Med.* Oct 24 2013;369(17):1587-97. doi:10.1056/NEJMoa1308789
6. Jolly SS, Cairns JA, Lavi S, et al. Thrombus Aspiration in Patients With High Thrombus Burden in the TOTAL Trial. *J Am Coll Cardiol.* Oct 2 2018;72(14):1589-1596. doi:10.1016/j.jacc.2018.07.047
7. Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). *Eur Heart J.* Jan 7 2018;39(2):119-177. doi:10.1093/eurheartj/ehx393
8. Brown ED, Blankenship JC. A mechanism for stroke complicating thrombus aspiration. *Catheter Cardiovasc Interv.* Jan 2017;89(1):93-96. doi:10.1002/ccd.26682
9. Gibson CM, de Lemos JA, Murphy SA, et al. Combination therapy with abciximab reduces angiographically evident thrombus in acute myocardial infarction: a TIMI 14 substudy. *Circulation.* May 29 2001;103(21):2550-4. doi:10.1161/01.cir.103.21.2550
10. Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial infarction. *Circulation.* Oct 16 2012;126(16):2020-35. doi:10.1161/CIR.0b013e31826e1058
11. Sianos G, Papafaklis MI, Serruys PW. Angiographic thrombus burden classification in patients with ST-segment elevation myocardial infarction treated with percutaneous coronary intervention. *J Invasive Cardiol.* Oct 2010;22(10 Suppl B):6B-14B.
12. Jolly SS, James S, Dzavik V, et al. Thrombus Aspiration in ST-Segment-Elevation Myocardial Infarction: An Individual Patient Meta-Analysis: Thrombectomy Trialists Collaboration. *Circulation.* Jan 10 2017;135(2):143-152. doi:10.1161/CIRCULATIONAHA.116.025371
13. Qin X, Luo J, Qin L, et al. Long-term Impact of Thrombus Aspiration in Patients With ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. *Am J Cardiol.* May 15 2020;125(10):1471-1478. doi:10.1016/j.amjcard.2020.02.025
14. Parodi G, Valenti R, Migliorini A, et al. Comparison of manual thrombus aspiration with rheolytic thrombectomy in acute myocardial infarction. *Circ Cardiovasc Interv.* Jun 2013;6(3):224-30. doi:10.1161/CIRCINTERVENTIONS.112.000172
15. Migliorini A, Stabile A, Rodriguez AE, et al. Comparison of AngioJet rheolytic thrombectomy before direct infarct artery stenting with direct stenting alone in patients with acute myocardial infarction.

The JETSTENT trial. *J Am Coll Cardiol*. Oct 12 2010;56(16):1298-306.

doi:10.1016/j.jacc.2010.06.011

16. De Carlo M, Aquaro GD, Palmieri C, et al. A prospective randomized trial of thrombectomy versus no thrombectomy in patients with ST-segment elevation myocardial infarction and thrombus-rich lesions: MUSTELA (MULTidevice Thrombectomy in Acute ST-Segment Elevation Acute Myocardial Infarction) trial. *JACC Cardiovasc Interv*. Dec 2012;5(12):1223-30. doi:10.1016/j.jcin.2012.08.013
17. Ali A, Cox D, Dib N, et al. Rheolytic thrombectomy with percutaneous coronary intervention for infarct size reduction in acute myocardial infarction: 30-day results from a multicenter randomized study. *J Am Coll Cardiol*. Jul 18 2006;48(2):244-52. doi:10.1016/j.jacc.2006.03.044
18. De Rosa S, Caiazzo G, Torella D, Indolfi C. Aspiration thrombectomy: an easily forgiven "latecomer". *J Am Coll Cardiol*. May 20 2014;63(19):2052-3. doi:10.1016/j.jacc.2013.12.038
19. Tung YC, See LC, Chang SH, Tu HT, Chan YH, Chang CJ. All-cause mortality and the risk of stroke with selective aspiration thrombectomy in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: A nationwide retrospective cohort study. *Medicine (Baltimore)*. May 29 2020;99(22):e19590. doi:10.1097/MD.00000000000019590
20. Grines CL, Nelson TR, Safian RD, Hanzel G, Goldstein JA, Dixon S. A Bayesian meta-analysis comparing AngioJet thrombectomy to percutaneous coronary intervention alone in acute myocardial infarction. *J Interv Cardiol*. Dec 2008;21(6):459-82. doi:10.1111/j.1540-8183.2008.00416.x
21. Navarese EP, Tarantini G, Musumeci G, et al. Manual vs mechanical thrombectomy during PCI for STEMI: a comprehensive direct and adjusted indirect meta-analysis of randomized trials. *Am J Cardiovasc Dis*. 2013;3(3):146-57.
22. Vergara R, Valenti R, Migliorini A, et al. Rheolytic Thrombectomy for Acute Myocardial Infarction Complicated by Cardiogenic Shock. *J Invasive Cardiol*. Dec 2016;28(12):E193-E197.
23. Rezaq A, Saad M. Thrombus aspiration in late presenters with ST-elevation myocardial infarction: A single-center randomized trial. *J Interv Cardiol*. Oct 2018;31(5):632-639. doi:10.1111/joic.12527

Figures




Figure 1

Study population. STEMI: ST-segment elevation myocardial infarction, TIMI: Thrombolysis In Myocardial Infarction, PCI: percutaneous coronary intervention, AT: AngioJet rheolytic thrombectomy, RT: routine treatment.




Figure 2

Kaplan–Meier Curves for Death from Any Cause.